Clinical trial · Observational
Prospective Observational Trial to Evaluate Quality of Life After Definitive Chemoradiation in Patients With Anal Cancer (LANACARE)
NCT03792854CI-TRIAL-00036321LANACARErecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Observational study to evaluate longitudinal quality of life according to standardized EORTC questionaires as well as functional outcome, oncological outcome and toxicity in patients treated with definitive chemoradiation for anal cancer
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anal Cancer | Malignant Anal Neoplasm | CURATED_EXACT | 0.92 |
| Chemoradiation | — | UNRESOLVED | — |
| Quality of Life | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| EORTC QLQ C30 | Other | — | UNRESOLVED |
| EORTC QLQ CR29 | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Qol (EORTC QLQC30) absolute values and change over time
- timeFrame
- day 0, end of week 6, 12, 19, 32, 58, 84, 110, 162, 214, 266
- description
- Quality of life measured by EORTC questionaire QLQC30 in absolute values at different time points and change over time
- measure
- Qol (EORTC QLQCR29) absolute values and change over time
- timeFrame
- day 0, end of week 6, 12, 19, 32, 58, 84, 110, 162, 214, 266
- description
- Quality of life measured by EORTC questionaire QLQCR29 in absolute values at different time points and change over time
Secondary outcomes (6)
- measure
- local control
- timeFrame
- end of week 6, 12, 19, 32, 58, 84, 110, 162, 214, 266
- description
- absence of disease progression inside the target volume of radiation therapy
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * histologically proven anal cancer without distant metastases * indication for definitive chemoradiation therapy based on multidisciplinary evaluation * age \>=18 years * written informed consent * ability to answer the standardized questionaires according to the treating physician Exclusion Criteria: * age \< 18 years * prior systemic therapy with regard to anal cancer * distant metastases * second malignancy
References
Publications (0)
Data not yet available
No reference posted for this study.